Spero Therapeutics, Inc. has recently filed a Form 3 with the SEC, which indicates a change in ownership involving William Ho, a director at the company. This filing is significant as it reflects the ongoing developments within the company and the broader pharmaceutical preparations sector.
Founded in Cambridge, Massachusetts, Spero Therapeutics, Inc. operates in the pharmaceutical preparations industry, classified under SIC code 2834. The company is publicly traded on the Nasdaq under the ticker symbol SPRO. Spero Therapeutics has been active in filing various forms with the SEC, including recent filings such as an 8-K and a 10-Q.
The Form 3 filing, dated November 10, 2026, specifically reports that William Ho is a director of Spero Therapeutics. The filing states, "The undersigned hereby constitutes and appoints each of Esther Rajavelu, Sheila Finan, and Maegan Deare of Spero Therapeutics, Inc., signing singly, with full power of substitution, as the undersigned’s true and lawful attorney-in-fact." This indicates that Ho has granted power of attorney to these individuals for specific legal and administrative purposes.
This change in ownership may affect various stakeholders, including investors and corporate governance within the company. As a director, Ho’s actions and decisions are closely monitored by the market, and any changes in his ownership status could influence investor perceptions of Spero Therapeutics.
Looking ahead, the filing does not specify what actions will follow this ownership change. However, it highlights the importance of transparency in corporate governance and the ongoing developments at Spero Therapeutics, which may attract attention from both investors and competitors in the pharmaceutical industry.
Read Next
Clark Kyle Sells 15,000 Shares of Beta Technologies Stock
Ronald R. Taylor resigns as director of ResMed Inc.
Afsari Nasym acquires 68,235 shares of Onterris, Inc.
Onterris, Inc. Chief Strategy Officer Acquires Shares
StubHub Holdings' Mark Streams Sells 76,891 Shares
Francesca M. Edwardson Transfers 25,000 Shares to Trust




